Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GbpB (also known as PdeE) is a class II dual-specificity phosphodiesterase found in the social amoeba Dictyostelium discoideum. It is a member of the metallo-beta-lactamase superfamily, characterized by a Zn2+-dependent hydrolase catalytic domain and two cyclic nucleotide-binding (cNB) domains. GbpB primarily hydrolyzes cAMP but also shows activity toward cGMP, playing a vital role in regulating the intracellular concentrations of these second messengers during the multicellular stages of development. Unlike mammalian class I PDEs, GbpB is insensitive to common inhibitors such as IBMX, making it a distinct target for studying non-canonical signaling pathways. Inactivation of GbpB leads to significantly elevated cAMP levels and a sporogeneous phenotype, underscoring its importance in the transition from vegetative growth to multicellular differentiation.
Hydrolysis of cAMP and cGMP
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual-specificity phosphodiesterase GbpB (GbpB).